Beskrivelse
Krav
Fullmektig i Norge:
Org.nummer: 979993269
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2015.06.29, US 201562186252 P
ALGULNIK, M: 'New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma.' CANCER. vol. 118, no. 6, 15 March 2012, pages 1486 - 1497, XP055061618 (B1)
Charlotte Benson ET AL: "A Retrospective Study of Patients with Malignant PEComa Receiving Treatment with Sirolimus or Temsirolimus: The Royal Marsden Hospital Experience", ANTICANCER RESEARCH, 1 January 2014 (2014-01-01), pages 3663-3668, XP055537945, Retrieved from the Internet: URL:http://ar.iiarjournals.org/content/34/ 7/3663.full.pdf [retrieved on 2019-01-02] (B1)
EL-HASHEMITE NISREEN ET AL: "Mutation inTSC2and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma", LANCET, vol. 361, no. 9366, 2003, pages 1348-1349, XP085425590, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(03)13044-9 (B1)
HENRY B ARMAH ET AL: "Malignant perivascular epithelioid cell tumor (PEComa) of the uterus with late renal and pulmonary metastases: a case report with review of the literature", DIAGNOSTIC PATHOLOGY, vol. 2, no. 1, 1 January 2007 (2007-01-01) , page 45, XP055537958, Lo ISSN: 1746-1596, DOI: 10.1186/1746-1596-2-45 (B1)
WO-A1-2014/144405 (B1)
MARK A. DICKSON ET AL: "Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates", INTERNATIONAL JOURNAL OF CANCER, vol. 132, no. 7, 21 September 2012 (2012-09-21), pages 1711-1717, XP055537941, US ISSN: 0020-7136, DOI: 10.1002/ijc.27800 (B1)
WAGNER A J ET AL: "ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial", JOURNAL OF CLINICAL ONCOLOGY 20190501 AMERICAN SOCIETY OF CLINICAL ONCOLOGY NLD, vol. 37, no. Supplement 15, 1 May 2019 (2019-05-01), ISSN: 1527-7755 (B1)
WO-A1-2008/109163 (B1)
LAO, IW ET AL.: 'Malignant Perivascular Epithelioid Cell Tumor (PEComa) of the Femur: a Case Report and Literature Review.' DIAGNOSTIC PATHOLOGY. vol. 10, no. 54, 29 May 2015, pages 1 - 6, XP055343511 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP3313401)
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende, AR454281650
Søknadsskjema Patent
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 9. avg. år (EP) | 2024.06.11 | 3710 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 8. avg. år (EP) | 2023.06.08 | 2550 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 7. avg. år (EP) | 2022.04.06 | 2200 | ENVOY INTERNATIONAL LIMITED | Betalt og godkjent |
32116926 expand_more expand_less | 2021.12.08 | 5500 | BRYN AARFLOT AS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|